Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Imdatifan · NKT-2152

Small molecule · Inhibitor of HIF-2alpha (EPAS1) · developed by NiKang Therapeutics

Phase 1/2 Most advanced trial
1 Registered trials

What is Imdatifan?

Imdatifan is an orally available inhibitor of HIF-2alpha, a transcription factor overexpressed in many cancer types. It binds HIF-2alpha to prevent heterodimerization and DNA binding, reducing expression of genes that promote tumor cell growth and survival. It is studied in advanced liver cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKT-2152
Drug type
Small molecule
Targets
HIF-2alpha (EPAS1)
Mechanism
Inhibitor of HIF-2alpha (EPAS1)
Pathways
transcription, tumor cell proliferation
Therapy area
Oncology
Developer
NiKang Therapeutics, Inc.
In trials of
ADAG
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
BL9SLT39J6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04524871 Phase 1/2 Advanced Liver Cancers Active not recruiting ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Liver Cancers

Other drugs acting on EPAS1

Belzutifan FDA approved Casdatifan Phase 1/2 Zifcasiran Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.